Anesiva – Dear Todd: (December 4th, 2003)
It is with great pleasure that I invite you to join the Corgentech team. We are building an exciting, new company dedicated to the discovery, development and commercialization of novel therapies for cardiovascular diseases and other significant health conditions. As you know, our most advanced product is entering Phase III clinical development and is projected to be approved for marketing in 2004. If successful, this product will alleviate a major cardiovascular health risk and thereby generate substantial revenues on a worldwide basis. We also have various research stage projects that we anticipate will result in additional clinical candidates.